REG - Hutchmed China Ltd - Total Voting Rights

HUTCHMED (China)Announcement

30/08/2024 09:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240830:nRSd1591Ca&default-theme=true

RNS Number : 1591C  Hutchmed (China) Limited  30 August 2024

 

Total Voting Rights

 

Hong Kong, Shanghai, & Florham Park, NJ - Friday, August 30, 2024:
HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM: HCM; HKEX: 13) hereby
notifies the market that as at August 30, 2024, the issued share capital of
HUTCHMED consisted of 871,469,720 ordinary shares of US$0.10 each, with each
share carrying one right to vote and with no shares held in treasury.

 

The above figure of 871,469,720 may be used by shareholders as the denominator
for the calculations by which they could determine if they are required to
notify their interest in, or a change to their interest in, HUTCHMED under the
Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

For illustrative purposes only, the 871,469,720 ordinary shares would be
equivalent to 871,469,720 depositary interests (each equating to one ordinary
share) which are traded on AIM or, if the depositary interests were converted
in their entirety, equivalent to 174,293,944 American depositary shares (each
equating to five ordinary shares) which are traded on Nasdaq.

 

 

About HUTCHMED

 

HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage,
biopharmaceutical company. Іt is committed to the discovery and global
development and commercialization of targeted therapies and immunotherapies
for the treatment of cancer and immunological diseases. Іt has approximately
5,000 personnel across all its companies, at the center of which is a team of
about 1,800 in oncology/immunology. Since inception HUTCHMED has focused on
bringing cancer drug candidates from in-house discovery to patients around the
world, with its first three medicines now marketed in China, the first of
which is also marketed in the US and Europe. For more information, please
visit: www.hutch‑med.com (https://www.hutch-med.com/) or follow us on
LinkedIn (https://www.linkedin.com/company/hutchmed/) .

 

 

Contacts

 

 Investor Enquiries                                                      +852 2121 8200 /
                                                                         ir@hutch-med.com (mailto:ir@hutch-med.com)

 Media Enquiries
 Ben Atwell / Alex Shaw, FTI Consulting                                  +44 20 3727 1030 / +44 7771 913 902 (Mobile) /
                                                                         +44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com
                                                                         (mailto:HUTCHMED@fticonsulting.com)
 Zhou Yi, Brunswick                                                      +852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
                                                                         (mailto:HUTCHMED@brunswickgroup.com)

 Nominated Advisor
 Atholl Tweedie / Freddy Crossley / Rupert Dearden, Panmure Liberum      +44 (20) 7886 2500

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRKZGZRRLVGDZG